NCT00860821View on ClinicalTrials.gov

A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2009

Study Completion Date

October 31, 2009

Conditions
Healthy
Interventions
DRUG

AZD8309

oral solution 30 mg/g, dose: 300mg bid for 3 days

DRUG

AZD8309

oral solution 30 mg/g, dose: 300mg bid for 3 days

Trial Locations (1)

Unknown

Research Site, Malmo

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY